N

Natalie Rutherford

The University of Melbourne

Publishes on Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment. 36 papers and 5.2k citations.

36Publications

5.2kTotal Citations

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Prostate Cancer Diagnosis and Treatment COVID-19 Clinical Research Studies Cancer Immunotherapy and Biomarkers

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al.|The Lancet|2020

Cited by 1.9k

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al.|The Lancet|2021

Cited by 1.1k

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al.|The Lancet Oncology|2022

Cited by 258

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al.|The Lancet Oncology|2023

Cited by 192

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al.|The Lancet Oncology|2024

Cited by 146